All In Biotech

Drug Trial Radar · NCT03652064

A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy

A Phase 3 Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Subjects With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy

Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 395 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

395

Actual

Start

Nov 6, 2018

Primary completion

May 7, 2024

Study completion Apr 21, 2026

Sponsor

Lead sponsor
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Aug 29, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study to determine if the addition of daratumumab to bortezomib + lenalidomide + dexamethasone (VRd) will improve overall minimal residual disease (MRD) negativity rate compared with VRd alone.

Conditions

  • Multiple Myeloma

Interventions

  • DaratumumabDrug

    Daratumumab (1800 mg) will be administered by SC injection once every week for Cycles 1 to 2, then every 3 weeks for Cycles 3-8. For Cycle 9 and beyond, participants will receive daratumumab 1800 mg SC once every 4 weeks until documented disease progression or unacceptable toxicity.

  • BortezomibDrug

    Bortezomib 1.3 mg/m\^2 will be administered by SC injection twice weekly on Days 1, 4, 8, and 11 of each 21-day cycle for Cycles 1-8.

  • LenalidomideDrug

    Lenalidomide will be self-administered at a dose of 25 mg orally on Day 1 to Day 14 for Cycles 1 through 8 and on Days 1 to 21 for Cycle 9 and beyond until disease progression or unacceptable toxicity whichever occurs first.

  • DexamethasoneDrug

    Dexamethasone will be self-administered orally, 20 mg on Days 1, 2, 4, 5, 8, 9, 11, 12 of each 21-day cycle for Cycles 1-8. During Cycle 9 and beyond dexamethasone, will be self-administered orally at a total dose of 40 mg on Days 1, 8, 15, 22 of each 28-day cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary Analysis: Overall Minimal Residual Disease (MRD) Negative RateTime frame: From randomization (Day 1) up to 27.9 months
  2. Final Progression-Free Survival (PFS) Analysis : Overall Minimal Residual Disease (MRD) Negative RateTime frame: From randomization (Day 1) up to 64.8 months

Locations

114 sites in 13 countries. Site status is shown where the registry gives one.

  • Innovative Clinical Research Inc

    Cerritos, California

  • Baptist MD Anderson

    Jacksonville, Florida

  • Fort Wayne Medical Oncology and Hematology, Inc.

    Fort Wayne, Indiana

  • Norton Healthcare

    Louisville, Kentucky

  • Tufts Medical Center

    Boston, Massachusetts

  • Boston University Medical Center

    Boston, Massachusetts

  • Cancer And Hematology Centers of Western Michigan PC

    Grand Rapids, Michigan

  • Saint Lukes Hospital Saint Lukes Cancer Specialists

    Kansas City, Missouri

  • Rutgers Cancer Institute of New Jersey

    New Brunswick, New Jersey

  • San Juan Oncology Associates

    Farmington, New Mexico

  • Roswell Park Cancer Institute

    Buffalo, New York

  • NYU Winthrop

    Mineola, New York

  • Levine Cancer Institute

    Charlotte, North Carolina

  • Cleveland Clinic

    Cleveland, Ohio

  • Good Samaritan Hospital Corvallis

    Corvallis, Oregon

  • University Of Pittsburgh Medical Center UPMC Hillman Cancer Center

    Pittsburgh, Pennsylvania

  • Gibbs Cancer Center

    Spartanburg, South Carolina

  • University of Texas, MD Anderson Cancer Center

    Houston, Texas

  • University of Virginia

    Charlottesville, Virginia

  • Universidade Estadual De Campinas

    Campinas, Brazil

  • Liga Norte Riograndense Contra O Cancer

    Natal, Brazil

  • Uniao Brasileira de Educacao e Assistencia Hospital Sao Lucas da PUCRS

    Porto Alegre, Brazil

  • Ministerio da Saude Instituto Nacional do Cancer

    Rio de Janeiro, Brazil

  • Instituto de Educacao, Pesquisa e Gestao em Saude Instituto Americas (COI)

    Rio de Janeiro, Brazil

  • Instituto de Ensino e Pesquisa São Lucas

    São Paulo, Brazil

  • Real e Benemerita Associacao Portuguesa de Beneficencia

    São Paulo, Brazil

  • Instituto Brasileiro de Controle do Cancer - Sao Camilo Oncologia

    São Paulo, Brazil

  • Hospital Santa Cruz

    São Paulo, Brazil

  • Clinica Medica Sao Germano S/S LTDA

    São Paulo, Brazil

  • Arthur J E Child Comprehensive Cancer Centre

    Calgary, Alberta, Canada

  • Cross Cancer Institute

    Edmonton, Alberta, Canada

  • The Gordon & Leslie Diamond Health Care Center

    Vancouver, British Columbia, Canada

  • QEII Health Sciences Centre

    Halifax, Nova Scotia, Canada

  • Brampton Civic Hospital

    Brampton, Ontario, Canada

  • Victoria Hospital

    London, Ontario, Canada

  • Lakeridge Health Oshawa

    Oshawa, Ontario, Canada

  • McGill University Health Centre

    Montreal, Quebec, Canada

  • CHU de Quebec L Hotel Dieu de Quebec

    Québec, Quebec, Canada

  • Fakultni nemocnice Brno

    Brno, Czechia

  • Fakultni nemocnice Hradec Kralove

    Hradec Králové, Czechia

Showing 40 of 114 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.